SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-22-024151
Filing Date
2022-11-10
Accepted
2022-11-10 07:12:11
Documents
16
Period of Report
2022-11-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K tals-20221110.htm   iXBRL 8-K 60331
2 EX-99.1 tals-ex99_1.htm EX-99.1 114600
3 GRAPHIC img186005553_0.jpg GRAPHIC 3366
4 GRAPHIC img186005553_1.jpg GRAPHIC 3366
5 GRAPHIC img186005553_2.jpg GRAPHIC 3366
  Complete submission text file 0000950170-22-024151.txt   319012

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT tals-20221110_pre.xml EX-101.PRE 10281
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT tals-20221110_lab.xml EX-101.LAB 14018
8 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT tals-20221110.xsd EX-101.SCH 2460
10 EXTRACTED XBRL INSTANCE DOCUMENT tals-20221110_htm.xml XML 4920
Mailing Address 93 WORCESTER STREET WELLESLEY MA 02481
Business Address 570 PRESTON ST. SUITE 400 LOUISVILLE KY 40202 502-398-9250
Talaris Therapeutics, Inc. (Filer) CIK: 0001827506 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40384 | Film No.: 221374907
SIC: 2836 Biological Products, (No Diagnostic Substances)